FDA/CMS Info Sharing Could Lead To Quicker Reimbursement Decisions, McClellan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS Administrator McClellan cites drug-eluting stents as an example of a new technology that received reimbursement immediately following product approval as a result of cooperation between the two agencies.